BCV
MRNA icon

Banque Cantonale Vaudoise’s Moderna MRNA Stock Holding History

Banque Cantonale Vaudoise’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$346 Buy
4,944
+3,821
+340% +$198K ﹤0.01% 573
2026
Q1 		$57K Hold
1,123
– – ﹤0.01% 760
2025
Q4 		$33K Sell
1,123
-426
-28% -$11.6K ﹤0.01% 742
2025
Q3 		$40K Sell
1,549
-3,083
-67% -$86K ﹤0.01% 717
2025
Q2 		$128K Sell
4,632
-9,957
-68% -$262K 0.01% 577
2025
Q1 		$413K Buy
+14,589
New +$518K 0.02% 478
2024
Q3 		$1.32M Sell
19,812
-9,318
-32% -$856K 0.05% 280
2024
Q2 		$3.46M Buy
29,130
+1,245
+4% +$158K 0.14% 143
2024
Q1 		$2.97M Sell
27,885
-4,539
-14% -$458K 0.12% 180
2023
Q4 		$3.23M Sell
32,424
-3,565
-10% -$300K 0.14% 143
2023
Q3 		$3.72M Buy
35,989
+2,833
+9% +$316K 0.19% 99
2023
Q2 		$4.03M Sell
33,156
-1,948
-6% -$260K 0.19% 101
2023
Q1 		$5.39M Buy
35,104
+3,063
+10% +$505K 0.26% 73
2022
Q4 		$5.76M Sell
32,041
-19,590
-38% -$3.2M 0.3% 63
2022
Q3 		$6.1M Sell
51,631
-3,433
-6% -$521K 0.35% 52
2022
Q2 		$7.87M Sell
55,064
-6,385
-10% -$913K 0.41% 45
2022
Q1 		$10.6M Sell
61,449
-6,742
-10% -$1.14M 0.46% 36
2021
Q4 		$17.3M Buy
68,191
+24,057
+55% +$7.03M 0.68% 21
2021
Q3 		$17M Sell
44,134
-16,601
-27% -$6.12M 0.73% 16
2021
Q2 		$14.3M Buy
60,735
+25,158
+71% +$4.5M 0.63% 21
2021
Q1 		$4.66M Buy
35,577
+19,347
+119% +$2.8M 0.24% 87
2020
Q4 		$1.7M Buy
16,230
+480
+3% +$48.6K 0.09% 196
2020
Q3 		$1.11M Buy
15,750
+12,768
+428% +$890K 0.07% 244
2020
Q2 		$192K Sell
2,982
-18
-0.6% -$986 0.01% 654
2020
Q1 		$90K Buy
+3,000
New +$69K 0.01% 780

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Banque Cantonale Vaudoise's MRNA Position: Q2 2026 in Review

Banque Cantonale Vaudoise increased its Moderna (MRNA) stake by 340% in Q2 2026, buying an estimated $198K and bringing the position to 4,944 shares worth $346. The position accounts for ﹤0.01% of the portfolio, ranked #573.

Banque Cantonale Vaudoise first reported a position in MRNA in Q1 2020 and has held it in 25 quarters since. The position peaked at $17.3M in Q4 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Banque Cantonale Vaudoise held 4,944 shares of Moderna worth $346 as of Q2 2026.
  • Banque Cantonale Vaudoise bought 3,821 Moderna shares in Q2 2026, an estimated $198K.
  • Moderna made up ﹤0.01% of Banque Cantonale Vaudoise's portfolio in Q2 2026, its #573 holding.
  • Banque Cantonale Vaudoise first reported a position in Moderna in Q1 2020 and has held it in 25 quarters since.
  • Banque Cantonale Vaudoise's Moderna position peaked at $17.3M in Q4 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Banque Cantonale Vaudoise's 13F filing for Q2 2026, filed 31 Jul 2026.